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3THE POMPIDOU GROUP
The Co-operation Group to Combat Drug Abuse and Illicit Trafficking I Drugs (Pompidou Group) is an 
intergovernmental body formed in 1971. Since 1980 it has carried out its activities within the 
framework of the Council of Europe. Thirty-five countries
1
  are now members of this European 
multidisciplinary forum, which allows policy makers, professionals and experts to exchange information 
and ideas on a whole range of drug misuse and trafficking problems. Its new mission, adopted at the 
Ministerial Conference in Dublin in October 2003, is to promote a dialogue and interaction between 
policy, practice and science with a special focus on the practical implementation of drug policies.
Through the setting up in 1982 of its group of experts in the epidemiology of drug problems, the 
Pompidou Group was a precursor for the development of drug research and monitoring of drug 
problems in Europe. The multi-city study, which aimed to assess, interpret and compare drug-use 
trends in Europe, is one of its major achievements. Other significant contributions include the piloting 
of a range of indicators and methodological approaches, particularly in the areas of school surveys, 
resulting in the ESPAD (European School Survey Project on Alcohol and other Drugs),
2
, treatment 
demand (Treatment demand indicator), prevalence estimation (Estimating the prevalence of problem 
drug use in Europe publication)
3
 and qualitative research. Over the years, the Pompidou Group has 
served as a key forum for epidemiological research and monitoring in Europe, including central and 
eastern Europe.
The Medspad project resulted from the Pompidou Group conference on Cooperation in the 
Mediterranean region which took place in Malta in 1999 under the patronage of the Ministry of Foreign 
Affairs, the Ministry of Social Politics, Sedqa (Service to Combat against Drug Dependence and 
Alcoholism) and the National Commission on the problems of drug dependence. The conference 
gathered together, for the first time, participants from Algeria, Egypt, Israel, Lebanon, Libya, Morocco 
and Tunisia.  As a result, two areas for action were decided upon. One concerned the needs in the 
field of demand reduction across a general overview of programmes, research work, policy and an 
inventory of practitioners in the field. The other focused on the need to evaluate the situation in the 
region, in order to follow and interpret the behaviour, levels and tendencies in drug use among 
adolescents and young adults. It is in this second area that the school survey began in the 
Mediterranean region. 
Despite difficulties encountered on a political and financial level, the Espad questionnaire was 
translated into Arab and tested in Algeria, Morocco and Libya a sample of students between 15-16 
years old. The report analyses the validity and reliability of data gathered during the first pilot studies 
and calls for a simplified version of the questionnaire.
1
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7PREFACE
The development of a questionnaire that addresses the issue of drug use among 15-16 year olds 
throughout Europe has as its early foundations in a PG working group that goes back to 1989. 
Subsequently, the 1994 report on the pilot survey conducted in six European countries paved the way 
for the first full survey of the European School survey Project on Alcohol and other Drugs (ESPAD) in 
1995 in which 26 European countries participated.  Following this first wave, a number of issues arose 
that were tackled successfully in a 1998 survey among eight countries in which issues of drunkenness 
and validity were tested and presented at the 25
th
 annual Alcohol Epidemiology Symposium in 
Montreal, Canada in 1999. The necessary changes were then adopted by all countries for the next 
survey that was conducted in 1999 among 30 European countries. In 2003 the third survey conducted 
in 35 European countries was carried out and the report is due at the end of 2004.
The success of the Pompidou Group ESPAD initiative demonstrated that it is possible to co-ordinate, 
collect, collate, compare and publish data in relation to the prevalence of alcohol and other drugs 
amongst youth. In much the same regard the Health Behaviour in School-aged Children (HBSC) study 
of the WHO has been able to collect specific data on health behaviour of young people in most 
European countries and those of North America. These two projects per se demonstrate that it is 
viable to collect reliable information on the behaviour of youth that in turn may be used by policy 
makers to address specific issues. The only apparent caveat is that the HBSC does not make any 
reference to drug use while both projects are mainly based on Western European society norms in the 
targeted population. 
In 1999 the Pompidou Group started activities in the Mediterranean region to promote cooperation and 
experience exchange in the field of drugs. In this context the Pompidou Group has initiated pilot 
surveys using the ESPAD methodology in order to test the viability of the ESPAD instrument in a 
different socio-cultural environment. In January 2003 a technical meeting in Rabat, Morocco, in which 
experts from the Pompidou Group, the UNODC Office for North Africa and the Middle East and 
several countries
4
 in the region participated, set the outlines for these pilot projects. Although the 
experts acknowledged that the ESPAD methodology, in particular its questionnaire instrument, has a 
strong European cultural bias, it was decided to leave the example methodology largely unchanged for 
the pilots and to discuss possible adaptations and modifications only after testing the existing 
instrument and analysing the validity and reliability of the pilot results.
At the Rabat meeting pilot surveys to be carried out in the spring of 2003 were planned in Morocco, 
Algeria and Egypt. In Algeria the pilot had to be postponed till the end of 2003 due to an earthquake in 
the envisaged pilot region (Boumerdes). In Egypt the pilot could not in the end be carried out due to 
organisational and financial reasons. Based on a cooperation agreement between the Pompidou 
Group and UNODC a third pilot however could be implemented early 2004 in Libya as part of a Rapid 
Situation Assessment of UNODC in Libya. 
This report presents the result of the analysis on validity and reliability of pilot school surveys in 
Algeria, Libya and Morocco. As the sampling procedures of the pilot surveys did not intend to generate 
representative population figures resulting data about the prevalence of drug use and other issues 
addressed in the survey only regard the schools selected and are therefore not presented in this 
report. 
4
 Morocco, Algeria, Egypt, Malta, Cyprus, France
81. SCOPE AND DESIGN OF THE PILOT SURVEYS
Questionnaire
All pilot surveys have used a slightly modified version of the original ESPAD 1999 questionnaire. In all 
surveys the question about the consumption of so-called “alcopops” was omitted as that this type of 
alcoholic drink was not yet available in the countries concerned. The research teams of Morocco, 
Algeria and Libya also made some other modifications by adding or deleting (sub)questions. The pilot 
questionnaire with their national variations is presented in Annex 1.
The questionnaire was presented to the pupils in an Arabic version, based on a translation by 
Dr.Amany Haroun el Rasheed (Egypt)
5
.  
Interview mode
All pilot surveys followed the ESPAD methodology of pen-and-paper completion of the questionnaire 
by pupils in a classroom setting under supervision of a member of the research team. The supervisor 
collected the completed questionnaires. In Algeria and Libya a code for the school has been added to 
the returned questionnaires.
Sampling 
In all countries the pilot survey has been carried out among a convenient sample of schools including 
general and vocational secondary education and covering areas with high and low socio-economic 
status. Within schools classes have been selected that were assumed to cover the intended age group 
of 15-16 year olds. Due to lack of data the research teams were not able to compare their samples 
with the total population of schools, classes and pupils in the areas concerned.
Differentiations by country
Characteristics of the pilot surveys and the actual samples used in Morocco, Algeria and Libya are 
presented below. 
MOROCCO
Coordinator: Dr.Jallal Toufiq. Survey area: Rabat region.
Sample of 11 schools: 9 high schools (“lycée”, general secondary education), 2 professional training 
schools (one for female students only). Selection criteria included: geographical environment (urban 7, 
semi-urban 1, rural 3), socio-economic status (low 6, middle 4, high 1). Size of sample frame: N = 413.
Response: N = 319; as no school codes have been recorded the response cannot be split by types of 
school or characteristics of the school location. 
Supervisors: school health educators (Ministry of Health) and teachers of the school hygiene bureaus 
(Ministry of Education and Youth).  
Filed work period: April 2003.
ALGERIA
Coordinator: Dr. Soumaya Mansouri Zeghnoun. Survey area: Boumerdes region (East of Alger).
Sample of 6 schools: 3 high schools (“lycée”, general secondary education); 3 colleges (vocational 
training centres); in each school type classes of 1
st
 and 2
nd
 level selected. High schools and colleges 
selected on the criterion of one of each in an urban, semi-urban and rural environment. Size of sample 
frame not recorded. Response: N = 430 (high schools 213, colleges 217). 
Supervisors: educational and career advisors working in each school.
Field work period: 2-10 April 2003. 
LIBYA
Coordinator: Dr.Ramadan Elghadaffi. Survey area: Tripoli metropolitan area.
Sample of 8 schools: 7 high schools (2 boys only, 4 girls only, 1 mixed), 1 technical vocational school 
(boys only). All high schools selected in middle class areas; vocational school in lower class area. Size 
of sample frame not recorded. Response: N = 994.
Supervisors: University students.
Field work period:  
5
 The Arabic version is not included in this report. A copy can be obtained from the Secretariat of the Pompidou 
Group Florence.MABILEAU-WHOMSLEY@coe.int]
92. SAMPLE AND RESPONSE ANALYSIS
The pilot surveys are based on convenient samples that more or less cover the variations in school 
types and socio-economic environments of the areas chosen (Boumerdes and surrounding area in 
Algeria, metropolitan Tripoli in Libya and Rabat and surrounding area in Morocco). The intention was 
to cover in all countries the mandatory school-going age group of 15-16 year olds, which would imply 
more or less equal numbers of boys and girls in the sample.
The results however show that the assumptions underlying the convenience sample are not consistent 
with the target group actually reached. The age group covered is much more varied, in particular in 
Morocco (Figure 1). Median as well as modal age is 15 in both Algeria and Libya and 16 in Morocco. 
In Algeria and Libya females are over-represented in the response (Figure 2); in the case of Libya 
where most schools are based on segregation of sexes, this overrepresentation is caused by the 
convenient sample (more girls- than boys schools selected); in the case of Algeria no explanation 
could be provided. 
As we don’t have information about the age and gender distributions of the school classes surveyed, 
we cannot assess if this deviation from the intended survey population is caused by the selection of 
schools and classes, incorrect assumptions about the expected age distributions in the selected 
classes or by non-response of the class populations addressed.
Figure 1: Age distributions in the response of the pilot samples 
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Figure 2: Gender distribution in the response of the pilot samples
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3. MISSING VALUES ANALYSIS
3.1 Introduction
We distinguish two types of missing values. First, missing values resulting from item non-response, 
and second, values that are declared as missing because of data entry errors (entering a code that 
doesn’t correspond to the pre-coded answer categories) or because the answer category itself implies 
that the respondent cannot (“don’t know”) or doesn’t want to reply to a question (refusal).
Item non-response, i.e. survey questions (items) that deliberately or inadvertently have been skipped 
by the respondents, affects the accuracy of the population estimates that statistically can be inferred 
from the survey data, as the net response for the items concerned will be lower than the overall 
response rate, which results in larger margins of error. When item non-response is not randomly 
distributed, it can also imply bias in the survey results.
In computer assisted surveys item non-response normally doesn’t occur because the software
prevents incorrect skipping of questions by requiring an answer to a question before one can move to 
the next one. Also in interviewer assisted surveys item non-response is usually rare when the 
interviewers are well trained and experienced. But in pen-and-paper self-completion surveys, like 
MedSPAD, item non-response can be a serious problem. Respondents may skip questions by 
mistake, but large numbers of skipped questions more likely indicate that they do not understand the 
questions or answer categories or that they feel uncomfortable with the content of the survey or do not 
want to answer particular questions, which in turn might indicate poor questionnaire design, failing 
completion instructions, inadequate survey introduction or might signal that the survey addresses 
issues that are beyond the interests or experiences of the target group. 
Declared missing values can have a similar effect on population estimates when they are caused by 
data entry errors, but their main problem is that they limit the options for analysis. Many “don’t know” 
answers can also indicate that a question is not appropriate for the target group.  
The purpose of the analysis below on the pilot school surveys of Algeria, Libya and Morocco is to 
assess the extent and patterns of missing values and to identify problems in the design and content of 
the MedSPAD questionnaire. 
3.2 Item non-response
The questionnaire of the MedSPAD pilot survey contains 46 (Algeria, Morocco) or 48 questions 
(Libya). Many questions however are split into sub-questions or have a table format in which the rows 
actually represent separate sub-questions. If we take these as separate questions the total number of 
questions varies from 190 (Morocco) to 191 (Algeria) and 196 (Libya). The questionnaire is designed 
in such a way that every respondent should answer each question; there are no instructions to skip 
questions on the basis of answers to preceding questions. Non-response is left blank in the survey 
data files (Algeria, Libya) or coded with a value that is labelled as “missing” (Algeria). 
The average percentage of questions skipped by the respondents varies from 10.5% (Algeria) to 
14.9% (Libya) and 17.2% (Morocco). In Morocco and Libya almost 50% and in Algeria almost 30% of 
the respondents skipped more than 10% of the questions; in Morocco 10% (Libya 8%, Algeria 5%) of 
the respondents skipped even more than 50% of the questions (Figure 3). 
This level of item non-response should be considered very high as most drug use school surveys
show less than 5% item non-response
6
. When non-response is very high, analysis of the items 
concerned will not give reliable results and researchers should reconsider or abandon the questions. 
Item non-response can also imply bias in the survey results if the non-response is associated with 
respondent attributes or other characteristics of the sampling. We have tested this for gender and age 
of the pupils and for the schools participating in the survey. 
The results, based on analysis of variances within and between groups, show that in Morocco and 
Libya boys skip more questions than girls; in Algeria it seems the opposite but the difference is not 
statistically significant (Table 1). In all countries older pupils skip more questions than younger ones, 
although in Libya pupils of over 17 skip less than 16 year olds (Table 2). 
6
 UNODC (2003), GAP Toolkit Module 3: Conducting School Surveys on Drug Abuse, p.74 
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Table 1: % skipped (sub) questions by gender
Gender Mean N Std. Dev. Sig.
Male 9.1 154 13.4
ALGERIA
Female 11.2 276 15.4
n.s.
Male 17.2 387 21.2
LIBYA
Female 13.4 592 16.7
0.002
Male 21.5 159 22.6
MOROCCO
Female 11.9 145 16.2
0.000
Table 2: % skipped (sub) question by age 
Age Mean N Std. Dev. Sig.
< 15 7.5 109 11.0
15 7.9 125 11.6
16 12.6 107 15.8
ALGERIA
17 + 15.3 87 19.5
0.000
< 15 11.9 345 14.0
15 15.0 386 19.5
16 22.3 100 25.3
LIBYA
17 + 17.3 82 20.8
0.000
< 15 7.2 38 10.1
15 11.2 62 15.3
16 15.6 68 19.3
MOROCCO
17 + 22.0 129 22.6
0.000
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At the level of individual schools item non-response varies from 3% to 26% in Algeria and from 9% to 
27% in Libya; the differences are statistically significant (Table 3). This implies that the setting (school) 
of the survey is a key factor for the non-response rates. For Morocco this relation could not be tested 
because the schools in which the survey took place have not been recorded in the data file. 
Table 3: % skipped (sub) questions per school
School Mean N Std. Dev. Sig.
Bordj Menaiel 10.5 72 10.9
Boumerdes 10.7 67 14.1
Cap Djinet 6.5 68 11.4
Corso 7.4 77 12.6
Ouled Moussa 3.0 77 3.4
ALGERIA
Sidi Daoued 25.9 69 20.1
0.000
School 1 17.6 121 20.1
School 2 26.6 85 29.3
School 3 13.0 138 16.7
School 4 11.8 112 15.5
School 5 14.7 157 19.8
School 6 9.2 116 9.6
School 7 13.7 126 14.9
LIBYA
School 8 16.0 138 18.1
0.000
We have also tested if item non-response relates to the type of question format. The results show that 
in general table formats with many sub-questions have higher non-response scores than single 
questions, in particular on the second and consecutive sub-questions (Table 4). This applies to all pilot 
surveys, although the differences are less prominent in the Algerian survey. 
A complete overview of the non-response per question is presented in Annex 1, which also shows that 
the Algerian pilot survey on almost all questions has less item non-response than the Libyan survey, 
whereas the Moroccan survey in most cases has the highest non-response rates. At the same time 
the overview reveals that in general in all pilot surveys high non-responses are found for the same
questions, which confirms the suggestion that non-response is related to the type of questions. 
Table 4: % skipped questions by type of question format
ALGERIA LIBYA MOROCCO
Single questions
6.2 7.6 6.6
Table format questions (average) 11.2 16.2 19.1
   First sub-question 8.4 8.9 10.0
   Consecutive sub-questions 11.6 17.1 20.2
Analysis of the response patterns in table format questions shows that if skipping occurs, the common 
patterns are to complete only the first sub-question, to halt somewhere halfway down the table or to 
skip everything, which suggests that the structure of these table formats is not always properly 
understood or explained in the completion instructions. 
In the case of table format questions that ask for life-time, last year and last month prevalence of 
substance use, skipping might be caused by the fact that a respondent considers asking for last year 
and last month prevalence obsolete when he already has already stated that he has never used the 
substance. This assumption can then be used to impute the missing data (see below). The response 
patterns of table format questions are presented in Annex 2. 
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3.3 Declared missing values
The data files that we used for the analysis had already been corrected for possible data entry errors. 
About one-third of all sub-questions have a pre-coded answer category that corresponds to “don’t 
know” and in most analyses this category would be treated as a missing value. 
Combining item non-response and “don’t know” answers substantially increases the percentages of 
missing values for Q9 (drinking alcohol at 25) and the sub-questions of Q32 (disapprovals), Q33 (risk 
perceptions) and Q34 (perceived availability of drugs). These combined percentages are specified in 
Annex 1.
4. IMPUTATION OF MISSING VALUES 
As mentioned before we observed many missing values in sub-questions that ask for last year and last 
month prevalence when the respondent has already denied lifetime prevalence in the preceding sub-
question. In these cases we can assume that the respondent has skipped the last year and last month 
questions because he thought that these didn’t apply to him. There are several other questions about 
substance use, in particular related to alcohol use, that in a similar way seem obsolete to the 
respondent when he has already stated that he didn’t use the substance. 
This type of item non-response can be corrected afterwards by imputing the missing values on the 
basis of the logical argument that once the use of a substance has been denied, skipping of any 
consecutive question, which phrasing refers to actual use of that substance, should be interpreted as 
confirming the previous denial of use.
Implementing these imputations on (sub)questions, which implicitly or explicitly require reconfirmation 
of previous answers, indeed results in a substantial reduction of missing values, in particular in the 
Libyan and Moroccan pilot surveys (Table 5). This suggests that either the instructions to the 
respondents should be improved or that the design of these questions should be reconsidered. The 
effects of the imputations on item non-response of individual (sub)questions are included in the 
overview of Annex 1. 
Table 5: Item non-response before and after imputation of missing values
Average % of item non-
response
Number of 
imputed 
questions
before 
imputation
after
imputation
ALGERIA 38 9.7 5.6
LIBYA 48 11.6 4.0
MOROCCO 39 15.1 5.7
5. VALIDITY
Validity refers to the extent to which the answers to the questions of a survey could be true. Large 
numbers of item non-response might indicate validity problems and the results of the missing values 
analysis above suggest that such problems do exist in the pilot surveys.
The MedSPAD questionnaire contains some questions that directly attempt to assess validity. Two 
questions ask for the respondent’s honesty with regard to self-reported cannabis (Q44) and heroin 
(Q45) use. As the answer patterns on Q44 and Q45 are very similar
7
, we present only results on Q44 
(honesty cannabis). Four table format questions, Q21 (having heard of), Q26 (lifetime prevalence), 
Q27 (age of onset) and Q28 (first drug), include a sub-question about a non-existent drug, which may 
indicate exaggeration of drug use.
7
 except the erratic results on Q45 in Algeria, which might have been caused by data entry errors. 
14
Honesty
The results with regard to honesty are not very positive. In Algeria and Morocco 32% and in Libya 46% 
of all respondents state that they would not have reported – probably not or definitively not – cannabis 
use if they actually would have used it. Considering also the relative high non-response rate on Q44 
(see Annex 1) we can hardly expect that the pilot surveys have produced valid cannabis prevalence 
rates and the same applies to heroin prevalence.
In most countries girls are more honest than boys (Table 6) and younger pupils are more honest than 
older ones (Figure 4) and these differences are statistically significant. Reported dishonesty of course 
does not mean that respondents have concealed actual drug use, but indicates that the questionnaire 
was not adequate to measure such use. Extending the survey population to older age groups, which is 
advocated by the research teams in all countries, might increase the number of respondents that 
actually have experienced some drug use, but the pilot results suggest that this at the same time 
would further decrease the validity of survey outcomes.
Table 6: Self-reported honesty regarding cannabis use in % of the response per gender
Already 
admitted
Definitive 
YES
Probably 
YES
Probably
NO
Definitive 
NO
Total
Male 14.7 46.0 8.7 8.7 22.0 100
Female 8.5 50.8 8.5 1.7 30.5 100
ALGERIA
Total 10.9 49.0 8.5 4.4 27.2 100
Male 6.7 35.9 6.3 4.1 47.0 100
Female 2.2 46.2 8.1 3.4 40.0 100
LIBYA
Total 4.0 42.2 7.4 3.7 42.7 100
Male 19.4 47.8 3.0 6.7 23.1 100
Female 7.1 51.6 6.3 5.6 29.4 100
MOROCCO
Total 13.5 49.6 4.6 6.2 26.2 100
Figure 4: Self-reported honesty regarding cannabis use in % of the response per age group
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References to Relevin
Despite the fact that 16% of the respondents in Algeria and Morocco and 8% in Libya claim to have 
heard of the non-existing drug Relevin listed in Q21, only one or two in each pilot survey report actual 
lifetime use. This dummy test drug therefore does not reveal any further validity problems. 
6. RELIABILITY
Reliability is a necessary, though not sufficient condition for validity and usually refers to the extent to 
which repeated measurements under the same conditions yield the same results. To assess the 
reliability of the results of a single survey a more practical way is to check for internal consistency of 
responses to different questions within the same questionnaire. 
The MedSPAD questionnaire has some build-in options for such consistency checks. For the purpose 
of this report the following have been explored:
- Life-time use of substances and age of first use of those substances (Algeria, Morocco; in Libya 
age of first use has not been recorded);
- Life-time, last year and last month prevalence of alcohol, cannabis and inhalants (Algeria, 
Morocco) or all substances (Libya);
- Honesty of responses on cannabis use and actual reported use of cannabis.
For most substances the Algerian and Moroccan pilot surveys (in Libya age of first use has not been 
recorded) the rates of inconsistency between reported life-time use (Q6 smoking, Q8a alcohol, Q23a 
cannabis, Q24a inhalants and Q26 for other drugs) and age of first use (Q27 for all substances) are 
very high, both for boys and girls (Table 7). In several cases inconsistent answers, i.e. admitting use in 
one question but denying it in the other, outnumber the consistent answers. The total numbers of 
users may be small, but given the observed inconsistencies the reported prevalences can hardly be 
considered reliable.
To some extent these inconsistencies may be related to the phrasing of the questions concerned, as 
there are subtle differences –at least in the original English or French versions- between the 
prevalence and the age of first use questions in wording and semantic meaning or interpretation. 
These differences may have been accentuated in the Arab version of the questionnaire.  
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Table 7: Inconsistencies between life-time prevalence of substance use and reported age of first use
Boys Girls Total
Country / 
substance
Valid N
Use 
reported
% in-
consis-
tent
Valid N
Use 
reported
% in-
consis-
tent
Valid N
Use
reported
% in-
consis-
tent
ALGERIA
Tobacco 152 72
27.8
258 4
50.0
410 76
28.9
Alcohol 151 8
0.0
263 2
50.0
414 10
10.0
Cannabis 148 17
35.3
260 4
25.0
408 21
33.3
Inhalants 147 16
87.5
259 6
66.7
406 22
81.8
Tranquillisers 147 9
55.6
263 8
50.0
410 17
52.9
Amphetamines 146 10
80.0
248 5
60.0
394 15
73.3
LSD 144 3
33.3
248 2
0.0
392 5
20.0
Crack 145 2
50.0
248 2
0.0
393 4
25.0
Cocaine 145 1
100.0
248 2
0.0
393 3
33.3
Relevin 145 0 248 2
0.0
393 2
0.0
Heroin 143 1
0.0
247 2
0.0
390 3
0.0
Ecstasy 145 0 248 2
0.0
393 2
0.0
MOROCCO
Tobacco 157 66
30.3
143 5
40.0
300 71
31.0
Alcohol 154 38
34.2
144 3
33.3
298 41
34.1
Cannabis 155 30
33.3
144 4
50.0
299 34
35.3
Inhalants 152 19
57.9
144 4
100.0
296 23
65.2
Tranquillisers 151 15
66.7
141 15
86.7
292 30
76.7
Amphetamines 136 8
37.5
138 6
66.7
274 14
50.0
LSD 132 4
75.0
137 0 269 4
75.0
Crack 132 3
100.0
137 0 269 3
100.0
Cocaine 131 2
50.0
137 1
100.0
268 3
66.7
Relevin 132 3
66.7
137 0 269 3
66.7
Heroin 131 1
100.0
137 0 268 1
100.0
Ecstasy 132 2
50.0
137 0 269 2
50.0
Rates of inconsistent answers on self-reported life-time, last year and last month prevalences for 
alcohol, cannabis and inhalants (Algeria, Morocco) or all substances covered in the questionnaire 
(Libya) are also very high (Table 8). Here inconsistencies can occur either by reporting last month or 
last year use after having denied last year or life-time use, or by reporting more frequent use in last 
month or last year than has been reported for last year or life-time use. Again total numbers of users 
are small, but the prevalences reported are far from consistent and therefore not reliable. In this case 
inconsistencies cannot be attributed to the phrasing of the questions
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Table 8: Inconsistencies between reported life-time, last year and last month prevalences
Boys Girls Total
Country / 
substance
Valid N
Use 
reported
% in-
consis-
tent
Valid N
Use 
reported
% in-
consis-
tent
Valid N
Use 
reported
% in-
consis-
tent
ALGERIA
Alcohol 149 9 44.4 255 1 100.0 404 10 50.0
Cannabis 148 15 26.7 257 3 33.3 405 18 27.8
Inhalants 146 16 6.3 258 6 16.7 404 22 9.1
LIBYA
Alcohol 371 13 23.1 568 3 66.7 939 16 31.3
Cannabis 380 12 16.7 585 9 11.1 965 21 14.3
Inhalants 377 9 22.2 584 1 0.0 961 10 20.0
Tranquillisers 380 10 50.0 584 9 44.4 964 19 47.4
amphetamines 353 11 45.5 559 6 66.7 912 17 52.9
LSD 353 5 40.0 556 0 909 5 40.0
Crack 352 3 33.3 556 0 908 3 33.3
Cocaine 352 3 100.0 556 0 908 3 100.0
Relevin 352 4 75.0 555 0 907 4 75.0
Heroin 353 3 66.7 555 0 908 3 66.7
ecstasy 352 4 75.0 555 0 907 4 75.0
Drug injecting 353 5 80.0 555 1 0.0 908 6 66.7
Alcohol+pills 380 5 40.0 590 0 970 5 40.0
Alcoh.cannabis 382 5 40.0 591 2 50.0 973 7 42.9
Hasj+marihuana 353 6 50.0 555 1 100.0 908 7 57.1
MOROCCO
Alcohol 156 35 34.3 143 3 33.3 299 38 34.2
Cannabis 156 31 25.8 143 3 0.0 299 34 23.5
Inhalants 153 21 47.6 144 4 0.0 297 25 40.0
Finally, comparing the responses on the honesty question Q44 about cannabis use shows that most 
respondents who declare that they “already said to have used cannabis” in fact previously had denied 
the use of cannabis in the prevalence question Q23a (Table 9). The reverse could be observed in 
Libya, where 6 out of 14 self-reported users declare that they “definitively would not have said so if 
they had used cannabis”. 
Table 9: Inconsistencies between self-reported cannabis use (Q23) and honesty with regard to 
cannabis use *Q44).
Boys Girls Total
Country / 
substance
Valid N
Already 
admitted 
(Q44)
% in-
consis-
tent
Valid N
Already 
admitted 
(Q44)
% in-
consis-
tent
Valid N
Already 
admitted 
(Q44)
% in-
consis-
tent
ALGERIA 142 21 76.2 219 19 94.7 364 42 85.0
LIBYA 312 21 90.5 488 11 90.9 801 32 90.6
MOROCCO 127 23 34.8 125 9 77.8 256 35 46.9
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7. CONCLUSIONS
• The analyses show that the results of the MedSPAD pilot surveys in Algeria, Libya and Morocco 
cannot be considered valid or reliable. Without substantial changes in methods and instruments a 
survey based on the European ESPAD model will not produce valid and reliable prevalence 
estimates for these countries. Considering the similarities in the problems encountered in all pilot 
countries, this might apply to all Arab countries.
• It is likely that validity and reliability problems relate to the content of the questionnaire itself. 
Pupils are not familiar with the situation of being subjects of a survey by means of a questionnaire 
with pre-coded answer categories and pupils are not used to the idea of reporting honestly about 
issues that are considered taboo or forbidden. This might be addressed by better preparation and 
instruction prior to administering the questionnaire, but it could also imply that the instrument is not 
appropriate to assess drug use prevalence in the countries involved. 
• Some of the validity and reliability problems might be solved by improving the design of the 
questionnaire, for example by reducing the number of table format questions, or by providing 
better instructions on how to complete the questions. 
• Based on a discussion of the results of the pilot surveys with the research teams a simplified 
alternative questionnaire (MEDSPAD) has been developed. This questionnaire is presented in 
Annex 4 and will be used as the model for an extensive survey in the greater Alger metropolitan 
area in the spring of 2005, which will also be supported by the Pompidou Group. 
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ANNEX 1:  MedSPAD QUESTIONNAIRE USED IN THE PILOT SURVEYS
Instructions for completion are not presented below. 
Modifications that apply to all pilot surveys are marked …… Modifications that apply only to Algeria are 
marked …..; modifications that apply only to Libya are marked …..
1. What is your sex?
Male θ
Female θ
2. When were you born?
Year: 19 θθ
3. How often (if at all) do you do each of the following? 
Never A few 
times a 
year
Once or 
twice a 
month
 At least 
once a 
week
Almost 
every 
day
a) Ride around on a moped or motorcycle just for fun
b) Play computer games
c) Actively participate in sports, athletics or exercising
d) Read books for enjoyment (do not count school books)
e) Go out in the evening (to a disco, cafe, party etc)
f) Other hobbies (play an instrument, sing, draw, write etc)
4. During the LAST 30 DAYS how many whole days of school have you missed and why?
Reasons None 1 day 2 days 3-4 days 5 - 6 days 7 days
or more
a) Because of illness      
b) Because you skipped or “cut”      
c) For other reasons      
5. Which of the following best describes your average grade in the end of the last term?
< COUNTRY SPECIFIC 5-POINTS SCALE >
6. On how many occasions (if any) during your lifetime have you smoked cigarettes?
0 1-2 3-5 6-9 10-19 20-39 40 and more
□ □ □ □ □ □ □
7. How frequently have you smoked cigarettes during the LAST 30 DAYS?
 Not at all
 Less than 1 cigarette per week
 Less than 1 cigarette per day
 1-5 cigarettes per day
 6-10 cigarettes per day
 11-20  cigarettes per day
 More than 20 cigarettes per day
8. On how many occasions (if any) have you had any alcoholic beverage to drink?
0 1-2 3-5 6-9 10-19 20-39 40 +
(a) In your lifetime       
(b) During the last 12 months       
(c) During the last 30 days       
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9. Do you think you will be drinking alcohol when you are twenty-five?
 No
 Yes
 I don‘t know
10. Think back over the LAST 30 DAYS. On how many occasions (if any) have you had any of the following 
to drink?  
0 1-2 3-5 6-9 10-19 20-39 40 +
(a) Beer (do not include low alcohol beer)       
(b) Wine       
(c) Spirits (whisky, cognac etc.) also include 
spirits mixed with soft drinks)
      
11. The last time you had an alcoholic drink, did you drink any beer/large/stout?  If so, how much? (Do not 
include low alcohol beer.)
 I never drink beer
 I did not drink beer on my last drinking occasion
 Less than a regular bottle or can (<50cl)
 1-2 regular bottles or cans  (50-100 cl)
 3-4 regular bottles or cans (101-200 cl)
 5 or more regular bottles or cans (> 200 cl)
QUESTION 12 RELATING TO ALCOPOPS WAS NOT USED IN THE PILOT SURVEYS (ALGERIA, MOROCCO, 
LIBYA)
13. The last time you had an alcoholic drink, did you drink any wine? If so, how much? (Include also wine 
mixed with other beverages.)
 I never drink wine
 I did not drink wine on my last drinking occasion
 Less than a glass (<10cl)
 1-2 glasses (10-20 cl)
 Half a bottle (37cl)
 A bottle or more (> 75 cl)
14. The last time you had an alcoholic drink, did you drink any spirits? If so, how much? (Include also spirits 
mixed with other beverages.)
 I never drink spirits
 I did not drink spirits on my last drinking occasion
 Less than a drink (< 5 cl)
 1-2 drinks (5-10 cl)
 3-4 drinks  (11-25  cl)
 6 drinks or more (> 30 cl) 
15. Think of the last day on which you drank alcohol. Where were you when you drank? (Mark all that apply.)
 I never drink alcohol
 At home
 At someone else‘s home
 Out on the street, in a park, beach or other open area
 At a bar or a pub
 In a disco
 In a restaurant
 Other places (please describe)______________________________________
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16. Think back over the LAST 30 DAYS. How many times (if any) have you had five or more drinks in a row? 
(A “drink” is a glass or wine (about 15 cl),  a bottle or can of beer (about 50 cl), a shot glass of spirits 
(about 5 cl) or a mixed drink.)
 None
 1
 2
 3-5
 6-9
 10 or more times
17. How likely is it that each of the following things would happen to you personally, if you drink alcohol? 
Very likely Likely Unsure Unlikely Very 
unlikely
(a) Feel relaxed     
(b) Get into trouble with police     
(c) Harm my health     
(d) Feel happy     
(e) Forget my problems     
(f) Not be able to stop drinking     
(g) Get a hangover     
(h) Feel more friendly and outgoing     
(i) Do something I would regret     
(j) Have a lot of fun     
(k) Feel sick     
(I) Feel guilty     
18. On how many occasions (if any) have you been drunk from drinking alcoholic beverages? 
0 1-2 3-5 6-9 10-19 20-39 40 +
(a) In your lifetime       
(b)During the last 
12 months
      
(c) During the last 30 days       
19. Please indicate on this scale from 1 to 10 how drunk you would say you were the last time you were 
drunk.
Somewhat merry Heavily intoxicated to the point of being unable to 
stand on my feet
I have never been drunk 
before
01 02 03 04 05 06 07 08 09 10 11
□ □ □ □ □ □ □ □ □ □ □
20. How many drinks do you usually need to get drunk? (A “drink” is a glass of wine (about 15 cl), a bottle or 
can of beer (about 50 cl), a shot glass of spirits (about 5 cl) or a mixed drink.)
 I never drink alcohol
 I have never been drunk
 1-2 drinks
 3-4 drinks
 5-6 drinks
 7-8 drinks
 9-10 drinks
 11-12 drinks
 13 drinks or more
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21. Have you ever heard of any of the following drugs? 
Yes No
(a) Tranquillisers or sedatives (valium)
□ □
(b) Marijuana or hashish
□ □
(c) LSD
□ □
(d) Amphetamines (speed)
□ □
(e) Crack
□ □
(f) Cocaine
□ □
(g) Relevin
□ □
(h) Heroin
□ □
(i) Ecstasy
□ □
(j) Methadone
□ □
22. Have you ever wanted to try any of the drugs mentioned in question 21?
 Yes
 No
23. On how many occasions (if any) have you used marijuana (grass, pot) or hashish (hash, hash oil)? 
No of times
0 1-2 3-5 6-9 10-19 20-39 40 plus
(a) In your lifetime
□ □ □ □ □ □ □
(b) During the last 12 months
□ □ □ □ □ □ □
(c) During the last 30 days
□ □ □ □ □ □ □
24. On how many occasions have you sniffed/inhaled a product (glue, aerosols) to obtain certain effects?
No of times
0 1-2 3-5 6-9 10-19 20-39 40 plus
(a) In your lifetime
□ □ □ □ □ □ □
(b) During the last 12 months
□ □ □ □ □ □ □
(c) During the last 30 days
□ □ □ □ □ □ □
25. Have you ever taken tranquillizers or sedatives because a doctor told you to take them?
1  No, never
2  Yes, but for less than 3 weeks
3  Yes, for 3 weeks or more
26. On how many occasions in your lifetime (if any) have you used any of the following drugs? 
No of times
0 1-2 3-5 6-9 10-19 20-39 40 plus
(a) Tranquillisers or sedatives
□ □ □ □ □ □ □
(b) Amphetamines (speed)
□ □ □ □ □ □ □
(c) LSD or acid
□ □ □ □ □ □ □
(d) Crack
□ □ □ □ □ □ □
(e) Cocaine
□ □ □ □ □ □ □
(f) Relevin
□ □ □ □ □ □ □
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No of times
(g) Heroin 
<no distinction made between different routes of 
administration>
□ □ □ □ □ □ □
(i) Ecstasy
□ □ □ □ □ □ □
(j) Drugs by injection with a needle  (like heroin, etc.)
□ □ □ □ □ □ □
(k) Alcohol together with pills
□ □ □ □ □ □ □
(l) Alcohol and marijuana at the same time
□ □ □ □ □ □ □
(m) Anabolic steroids
(ALGERIA only)
□ □ □ □ □ □ □
(n) Hashish and marijuana
(LIBYA only)
□ □ □ □ □ □ □
<in LIBYA question 26 has also been asked with regard to last 12 months and last 30 days>
27. When (if ever) did you FIRST do each of the following things?
<question not asked in Libya>
Never 11 yrs 12 yrs 13 yrs 14 yrs 15 yrs 16 yrs
(a) Drink beer
(at least one glass)       
(b) Drink wine
(at least one glass)       
(c) Drink spirits
(at least one glass)       
(d) Get drunk on alcohol       
(e) Smoke your first cigarette       
(f) Smoke cigarettes on a daily basis       
(g) Try amphetamines       
(h) Try tranquillizers or sedatives 
(without a doctor‘s prescription)
      
(i) Try marijuana or hashish       
(j) Try LSD or some other 
hallucinogen
      
(k) Try crack       
(l) Try cocaine       
(m) Try relevin       
(n) Try ecstasy       
(o) Try Heroin       
(p) Try inhalants (glue etc) to get high       
(q) Try anabolic steroids       
28. What was the first drug (if any) that you have ever tried?
 I have never tried any of the substances listed below
 Tranquillizers or sedatives without a doctor‘s prescription
 Marijuana or hashish
 LSD
 Amphetamines
 Crack
 Cocaine
 Relevin
 Heroin
 Ecstasy
 I don‘t know what it was
29. How did you get this substance?
 I have never used any of the substances listed in question 28.
 Given to me by an older brother or sister
 Given to me by a friend, a boy or a girl, older than me
 Given to me by a friend my own age or younger
 Given to me by someone I have heard about but did not know personally
 Given to me by a stranger
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 It was shared around a group of friends
 Bought from a friend
 Bought from someone I have heard about but did not know personally
 Bought from a stranger
 Given to me by one of my parents
 Took it at home without my parents’ permission
 None of these (please describe briefly how you did get it)....................................................................
30. Which was the reason(s) for you to try this drug? 
 I have never used any of the substances listed in question 28.
 I wanted to feel high
 I did not want to stand out from the group
 I had nothing to do
 I was curious
 I wanted to forget my problems
 Other reason (s), please specify ...........................................................................................................
 I don‘t remember
31. In which of the following places do you think you could easily buy marijuana or hashish if you wanted to? 
 I don‘t know of any such place
 Street, park etc.
 School
 Disco, bar etc
 House of a dealer
 Other(s), please specify ........................................................................................................................
32. Individuals differ in whether or not they disapprove of people doing certain things. DO YOU 
DISAPPROVE of people doing each of the following? 
Don’t Disapprove Strongly Don’t 
disapprove disapprove know
(a) Smoking cigarettes occasionally    
(b) Smoking 10 or more cigarettes a day    
(c) Drinking 1 or 2 drinks of an alcoholic beverage a
few times a year (beer, wine, spirits)    
(d) Having one or two drinks several times a week    
(e) Getting drunk once a week    
(f) Trying marijuana or hashish (cannabis, pot, grass)
once or twice    
(g) Smoking marijuana or hashish occasionally    
(h) Smoking marijuana or hashish regularly    
(i) Trying LSD or some other hallucinogen
once or  twice    
(j) Trying heroin (smack, horse) once or twice    
(k) Trying tranquillizers or sedatives (without a    
doctor ‘s prescription) once or twice
(l) Trying an amphetamine (speed) once or twice    
(m) Trying crack once or twice    
(n) Trying cocaine once or twice    
(o) Trying ecstasy once or twice    
(p) Trying inhalants (glue, etc.) once or twice    
33. How much do you think PEOPLE RISK harming themselves (physically or in other ways) if they. …
Don’t No Slight Moderate Great
Know risk risk risk risk 
(a) smoke cigarettes occasionally     
(b) smoke one or more packs of cigarettes per day     
(c) have one or two drinks nearly every day     
(d) have four or five drinks nearly every day     
(e) have five or more drinks each weekend     
(f) try marijuana or hashish once or twice     
(g) smoke marijuana or hashish occasionally     
(h) smoke marijuana or hashish regularly     
(i) try LSD once or twice     
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Don’t No Slight Moderate Great
Know risk risk risk risk 
(j) take LSD regularly     
(k) try an amphetamine (speed) once or twice     
(l) take amphetamines regularly     
(m) try cocaine or crack once or twice     
(n) take cocaine or crack regularly     
(o) try ecstasy once or twice     
(p) take ecstasy regularly     
(q) try inhalants (glue, etc.) once or twice     
(r) take inhalants (glue, etc.) regularly     
34. How difficult do you think it would be for you to get each of the following if you wanted? 
Impossible Very Fairly Fairly Very Don‘t
difficult difficult easy easy know
(a) Cigarettes      
(b) Beer      
(c) Wine      
(d) Liquor      
(e) Marijuana/ hashish      
(f) LSD or some hallucinogen      
(g) Amphetamines (speed)      
(h) Tranquillizers or sedatives      
(i) Crack      
(j) Cocaine      
(k) Ecstasy      
(l) Heroin (smack)      
(m) Inhalants (glue, etc)      
(n) Anabolic steroids      
(not asked in LIBYA)
() Home-made alcohol      
35. How many of your friends would you estimate … 
None A few Some Most All
(a) Smoke cigarettes     
(b) Drink alcoholic beverages (beer, wine, spirits)     
(c) get drunk at least once a week     
(d) smoke marijuana (grass) or hAshish     
(e) take LSD or some other hallucinogen     
(f) take amphetamines (Speed)     
(g) take tranquillizers or sedatives 
(without a doctor‘s prescription)     
(h) take cocaine or crack     
(i) take ecstasy     
(j) take heroin     
(k) take inhalants (glue, etc)     
(l) take alcohol together with pills     
(m) take anabolic steriods     
36. Have you ever had any of the following problems?
Never Yes, because Yes, because Yes for
   of alcohol    of drugs other
(a) Quarrel or argument    
(b) Scuffle or fight    
(c) Accident or injury    
(d) Loss of money or other valuable items    
(e) Damage to objects or clothing    
(f) Problems in your relationship with 
your parents    
(g) Problems with your relationship with 
your friends    
(h) Problems with your relationship with 
your teachers    
(i) Performed poorly at school or work    
(j) Victimized by robbery or theft    
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Never Yes, because Yes, because Yes for
   of alcohol    of drugs other
(k) Trouble with police    
(l) Hospitalised or admitted to an 
emergency room    
(m) Engaged in sex you regretted the 
next day    
(n) Engaged in unprotected sex    
(o) Drunk driving    
(only asked in ALGERIA)
37. Does any of your elder siblings…
Never Seldom Sometimes Often Don’t Don’t have
Know       elder siblings
(a) smoke cigarettes      
(b) drink alcoholic beverages
(beer, wine,spirits)      
(c) get drunk      
(d) smoke marijuana or hashish      
(e) take tranquillizers or 
sedatives (without a 
doctor’s prescription)      
(g) take tranquillizers or 
sedatives as medication      
(h) take heroin      
(f) take ecstasy      
(i) take cocaine      
38. What is the highest level of schooling your father completed?
 Completed primary school or less
 Some secondary school
 Completed secondary school
 Some college or university
 Completed college or university
 Don’t know or does not apply
39. What is the highest level of schooling your mother completed?
 Completed primary school or less
 Some secondary school
 Completed secondary school
 Some college or university
 Completed college or university
 Don’t know or does not apply
40. How well off is your family compared to other families in your country?
 Better off
 About the same
 Less well off
41. Which of the following people live in the same household with you?
 I live alone
 Father
 Stepfather
 Mother
 Stepmother
 Brother (s) and/or sister (s)
 Grandparent (s)
 Other relative (s)
 Non-relative (s)
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42. How satisfied are you usually with
Very Satisfied Neither satisfied Not so Not at all
satisfied or not satisfied satisfied satisfied
(a) your relationship with your mother?     
(b) your relationship with  your father?     
(c) your relationship with your friends?     
43. Do your parents know where you spend Saturday evenings?
 Know always
 Know quite often
 Know sometimes
 Usually don‘t know
44. If you had ever used marijuana or hashish, do you think that you would have said so in this 
questionnaire?
 I already said that I have used it
 Definitely yes
 Probably yes
 Probably not
 Definitely not
45. If you had ever used heroin, do you think that you would have said so in this questionnaire?
 I already said that I have used it
 Definitely yes
 Probably yes
 Probably not
 Definitely not
46. How much money do you usually spend a week for your personal needs, and where do you get it from?
How much money do you spend a week?
……………. <local currency>.
From where do you get the money?
θ A paid job
θ Parents or other relatives
 Other sources
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ANNEX 2: ITEM NON-RESPONSE AND MISSING VALUES in % PER (SUB)QUESTION
The column “item non-response + declared missing values” in the table below only presents figures if 
declared missing values exist as pre-coded categories. The column “item non-response after 
imputation” presents only figures if imputations have been made.
< 5%
5-15%
15-30%
> 30%
ALGERIA LIBYA MOROCCO
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
(Sub)
question
Label
% % % % % % % % %
Q1
Sex
0.0 1.5 4.7
Q2
Age
0.5 8.1 6.9
Q3
Doing things
Q3a
Doing ride
4.2 5.4 2.8
Q3b
Doing games
4.4 7.7 7.5
Q3c
Doing sport
6.5 9.0 6.3
Q3d
Doing read
3.7 8.9 6.3
Q3e
Doing party
6.0 8.6 7.8
Q3f
Doing other
72.6 30.8 6.6
Q4
Missing school
Q4a
Absent illness
9.3 14.8 12.9
Q4b
Absent skipped
41.4 43.0 42.0
Q4c
Absent other
71.2 35.1 29.8
Q5
Grade
1.2 9.2 4.7
Q6
LTF smoke
6.0 3.1 1.6
Q7
LMF smoke
3.3 2.1 4.9 2.0 3.1 1.9
Q8
Prevalence alcohol
Q8a
LTF alcohol
6.7 4.3 4.1
Q8b
LYF alcohol
16.5 6.7 32.3 5.0 29.2 6.0
Q8c
LMF alcohol
17.4 7.7 32.4 5.0 28.5 6.0
Q9
Drink 25
5.8 17.7 3.6 13.9 6.0 21.9
Q10
Last month prevalence alcoholic drinks
Q10a
LMF beer
10.0 6.0 6.7 2.1 5.3 2.8
Q10b
LMF wine
12.8 8.8 15.3 10.7 16.6 14.1
Q10c
LMF spirits
12.8 8.8 14.5 9.9 16.3 13.8
Q11
Last=beer
4.4 3.7 3.7 0.9 4.1 1.9
Q13
Last=wine
4.7 4.0 4.2 1.1 3.1 0.9
Q14
Last=spirits
4.7 4.0 4.0 1.4 4.1 1.3
30
ALGERIA LIBYA MOROCCO
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
(Sub)
question
Label
% % % % % % % % %
Q15
Where drink
4.7 3.7 2.3 0.7 2.8 1.3
Q16
LMF 5 drinks
4.7 0.0 2.4 0.3 3.1 0.3
Q17
Perceived effects of alcohol
Q17a
Relaxed
25.6 42.3 37.6
Q17b
Police
21.6 44.2 37.9
Q17c
Health
19.1 37.1 29.5
Q17d
Happy
26.7 46.2 40.1
Q17e
Forget
28.8 46.5 40.8
Q17f
No stop
29.1 47.0 40.8
Q17g
Hangover
26.0 44.7 38.6
Q17h
Friendly
28.6 47.7 42.3
Q17i
Regret
25.6 45.9 39.2
Q17j
Fun
27.9 40.7 35.1
Q17k
Sick
24.2 47.0 41.4
Q17l
Guilty
19.8 44.0 37.6
Q18
Prevalence of drunkenness
Q18a
LTF drunk
8.1 4.9 5.0 0.7 7.5 3.8
Q18b
LYF drunk
15.6 4.9 29.1 0.9 32.0 5.0
Q18c
LMF drunk
15.3 4.4 29.1 0.8 32.0 4.7
Q19
How drunk
5.6 9.3 
8
24.3 6.9
Q20
Amount drunk
5.6 3.5 3.0 0.2 5.6 1.9
Q21
Having heard of drugs
Q21a
Heard tranq.
35.3 16.6 35.7
Q21b
Heard cannabis
6.5 12.0 12.9
Q21c
Heard LSD
18.6 20.0 35.7
Q21d
Heard amphet.
21.9 21.0 38.9
Q21e
Heard crack
20.5 20.5 36.7
Q21f
Heard cocaine
7.9 17.1 19.4
Q21g
Heard relevin
20.5 19.9 37.9
Q21h
Heard heroin
9.8 13.8 26.3
Q21i
Heard ecstasy
20.7 20.9 37.3
Q21j
Heard methad.
20.9 20.1 37.6
Q22
Want try drug
9.1 4.6 4.7
Q23
Prevalence cannabis
Q23a
LTF cannabis
6.7 1.6 3.8
8
 Including data entry errors recoded into missing by the authors
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ALGERIA LIBYA MOROCCO
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
(Sub)
question
Label
% % % % % % % % %
Q23b
LYF cannabis
12.3 6.0 24.4 1.8 31.0 6.6
Q23c
LMF cannabis
13.0 6.7 24.6 1.9 30.4 5.6
Q24
Prevalence sniffing
Q24a
LTF sniff
6.0 1.8 3.4
Q24b
LYF sniff
13.7 7.4 25.9 2.2 30.7 4.7
Q24c
LMF sniff
13.7 7.4 25.7 2.2 30.4 4.1
Q25
Prescr. tranq.
2.8 3.2 1.9
Q26
Lifetime prevalence of drugs
Q26a
LTF tranq.
5.8 3.5 6.0
Q26b
LTF amphet.
9.1 9.0 12.5
Q26c
LTF LSD
9.5 9.0 13.8
Q26d
LTF crack
9.3 9.0 13.5
Q26e
LTF cocaine
9.3 9.0 13.8
Q26f
LTF relevin
9.3 9.1 13.5
Q26g
LTF heroin
9.3 9.3 13.5
Q26i
LTF ecstasy
9.3 9.6 13.5
Q26j
LTF injecting
9.5 9.4 13.8
Q26k
LTF alc.+pills
9.5 5.3 9.5 1.2 13.8 4.1
Q26l
LTF alc.+cann.
9.5 3.5 9.1 0.7 11.9 1.6
Q26m
LTF steroids
9.5
Q26n
LTF hasj+mari.
9.1
Q26_2
Last month prevalence of drugs (LIBYA only)
Q26_2a
LMF tranq.
4.9 1.8
Q26_2b
LMF amphet.
10.4 6.9
Q26_2c
LMF LSD
10.5 7.1
Q26_2d
LMF crack
10.9 7.2
Q26_2e
LMF cocaine
10.6 7.2
Q26_2f
LMF relevin
10.6 7.3
Q26_2g
LMF heroin
10.4 7.3
Q26_2i
LMF ecstasy
10.5 7.4
Q26_2j
LMF injecting
10.7 7.3
Q26_2k
LMF alc.+pills
10.5 1.0
Q26_2l
LMF alc.+cann.
10.4 0.7
Q26_2n
LMF hasj+mari.
10.4 7.4
Q26_3
Last year prevalence of drugs (LIBYA only)
Q26_3a
LYF tranq.
5.0 2.0
Q26_3b
LYF amphet.
10.1 7.2
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Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
(Sub)
question
Label
% % % % % % % % %
Q26_3c
LYF LSD
10.2 7.2
Q26_3d
LYF crack
10.3 7.3
Q26_3e
LYF cocaine
10.4 7.3
Q26_3f
LYF relevin
10.4 7.4
Q26_3g
LYF heroin
10.6 7.5
Q26_3i
LYF ecstasy
10.3 7.5
Q26_3j
LYF injecting
10.3 7.4
Q26_3k
LYF alc.+pills
10.7 1.0
Q26_3l
LYF alc.+cann.
10.8 0.7
Q26_3n
LYF hasj+mari.
10.7 7.6
Q27
Age of first use substances
Q27a
Age beer
5.1 4.0 6.9 3.4
Q27b
Age wine
10.2 5.8 14.1 4.7
Q27c
Age spirits
10.5 5.8 15.0 4.4
Q27d
Age drunk
10.2 3.7 14.1 3.8
Q27e
Age first cig
9.8 5.1 13.2 6.0
Q27f
Age day smoke
10.7 16.0
Q27g
Age amphet.
10.9 8.8 15.4 11.0
Q27h
Age tranq.
10.5 4.7 15.4 5.3
Q27i
Age cannabis
10.7 5.6 16.9 5.0
Q27j
Age LSD
10.5 17.6
Q27k
Age crack
10.2 8.6 16.9 11.3
Q27l
Age cocaine
10.2 8.6 17.2 11.6
Q27m
Age relevin
10.5 8.6 17.2 11.6
Q27n
Age ecstasy
10.7 8.6 17.2 11.6
Q27o
Age heroin
17.2 11.6
Q27p
Age sniff
10.9 5.8 16.9 4.4
Q27q
Age steroids
10.5 8.6 20.7 20.7
Q28
First drug
4.4 4.7 3.0 2.1 2.3 0.4 5.3 6.6 2.2
Q29
How obtained
5.3 3.0 3.2 0.4 5.3 1.3
Q30
Reason taking
5.1 3.0 2.5 0.5 3.4 1.3
Q31
Easy buy can.
5.3 3.7 6.9
Q32
Disapproval substance use
Q32a
Smoke occas.
2.6 8.6 6.0 16.0 4.7 11.9
Q32b
Smoke 10
3.7 6.7 11.8 19.1 13.8 16.9
Q32c
Drink few year
2.8 8.1 11.7 19.3 12.9 16.6
Q32d
Drink 1-2 week
12.0 19.3 16.6 20.1
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ALGERIA LIBYA MOROCCO
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
(Sub)
question
Label
% % % % % % % % %
Q32e
Drunk once wk
2.8 6.7 12.1 20.0 16.0 18.5
Q32f
Cannabis try
3.5 7.9 12.0 19.6 16.0 19.4
Q32g
Cannabis occ.
2.8 7.9 12.5 19.5 16.9 19.7
Q32h
Cannabis reg.
2.8 8.8 12.1 19.5 16.0 19.1
Q32i
LSD try
3.5 10.2 12.8 20.2 17.6 20.4
Q32j
Heroin try
4.2 10.9 12.2 19.6 17.6 21.0
Q32k
Tranquill. try
3.3 12.1 12.4 20.7 18.2 21.3
Q32l
Amphet. Try
3.7 10.0 12.2 20.0 16.6 19.4
Q32m
Crack try
3.7 10.0 12.4 19.7 17.6 21.0
Q32n
Cocaine try
3.7 8.6 12.3 19.4 17.6 20.4
Q32o
Ecstasy try
4.4 10.9 12.3 19.7 17.2 20.4
Q32p
Sniff try
4.0 10.7 12.3 19.7 16.9 19.7
Q33
Risk perception substance use
Q33a
Smoke occas.
1.4 12.3 7.9 35.5 4.7 31.3
Q33b
Smoke heavy
2.3 10.0 13.0 36.6 10.7 25.7
Q33c
Drink 1-2 day
2.6 14.4 13.7 39.5 11.6 26.0
Q33d
Drink 4-5 day
3.3 15.1 13.9 39.1 12.5 27.9
Q33e
Drink 5 wk’end
3.3 15.6 14.6 40.0 11.0 25.1
Q33f
Cannabis try
3.3 17.9 13.6 40.5 11.6 30.7
Q33g
Cannabis occ.
4.4 19.8 14.4 40.9 14.4 35.1
Q33h
Cannabis reg.
4.0 18.6 13.9 39.5 14.4 31.0
Q33i
LSD try
4.0 21.6 14.5 44.1 15.0 34.5
Q33j
LSD regular
3.7 19.8 14.3 43.4 15.7 34.8
Q33k
Amphet. Try
5.1 23.0 14.3 44.2 15.0 36.1
Q33l
Amphet. regular
3.7 21.6 14.5 43.4 16.0 36.4
Q33m
Cocaine try
4.0 21.6 14.2 43.1 15.0 32.9
Q33n
Cocaine regular
4.9 21.4 14.3 42.2 14.7 32.6
Q33o
Ecstasy try
8.1 24.4 14.0 43.6 15.4 35.4
Q33p
Ecstasy regular
8.4 23.7 14.1 42.8 15.7 35.1
Q33q
Sniff try
7.9 25.6 14.0 42.4 16.0 33.9
Q33r
Sniff regular
8.4 27.9 14.0 42.5 14.7 33.5
Q34
Perceived availability of substances
Q34a
Easy cigs
5.1 14.4 10.6 21.6 8.8 27.0
Q34b
Easy beer
7.4 20.7 15.8 27.6 13.5 30.1
Q34c
Easy wine
8.1 23.5 16.2 28.5 15.7 34.2
Q34d
Easy spirits
8.1 20.9 16.4 28.1 16.0 32.9
Q34e
Easy cannabis
8.6 22.1 16.6 28.4 15.4 33.5
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ALGERIA LIBYA MOROCCO
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
(Sub)
question
Label
% % % % % % % % %
Q34f
Easy LSD
9.3 24.9 16.5 29.2 16.3 37.0
Q34g
Easy amphet.
8.4 24.7 16.9 29.6 17.2 39.5
Q34h
Easy tranquill.
8.1 23.5 16.3 28.7 16.6 37.0
Q34i
Easy crack
8.8 26.7 16.8 29.9 17.6 38.9
Q34j
Easy cocaine
8.6 24.9 16.5 29.0 16.6 37.3
Q34k
Easy ecstasy
8.8 25.8 16.5 29.6 17.9 39.5
Q34l
Easy heroin
9.5 26.3 16.7 28.6 17.6 38.6
Q34m
Easy sniff
8.4 22.6 16.5 28.9 16.9 35.4
Q34n
Easy steroids
9.3 31.2 18.2 43.6
Q34o
Easy home alc.
8.4 28.1 16.4 28.2 16.6 39.2
Q35
Substance use of friends
Q35a
Friends smoke
2.8 4.9 3.1
Q35b
Friends drink
5.8 10.7 12.5
Q35c
Friends drunk
6.5 10.8 13.2
Q35d
Friends cann.
6.7 11.1 12.9
Q35e
Friends LSD
7.4 11.0 15.4
Q35f
Friends amph.
7.9 11.0 15.4
Q35g
Friends tranq.
7.0 11.0 16.0
Q35h
Friends cocaine
7.2 11.2 15.0
Q35i
Friends ecstasy
7.4 11.2 16.3
Q35j
Friends heroin
7.4 11.3 16.6
Q35k
Friends sniff
7.7 11.1 15.4
Q35l
Friends alc/pills
7.7 20.7
Q35m
Friends steroids
7.4
Q36
Problems due to alcohol or drugs (ALGERIA: due to alcohol only)
Q36a
Quarrel
11.2 15.8 22.9
Q36b
Fight
16.3 21.4 29.8
Q36c
Accident
16.3 22.1 29.5
Q36d
Loss
16.5 21.8 30.4
Q36e
Damage
16.3 21.9 31.0
Q36f
Probl. Parents
16.5 22.1 30.7
Q36g
Probl. Friends
16.5 22.3 31.3
Q36h
Probl. Teachers
16.3 22.2 30.4
Q36i
Poor perform
16.3 22.7 30.7
Q36j
Victim
16.5 22.3 31.0
Q36k
Police
16.5 22.5 31.0
Q36l
Hospital
16.5 22.5 31.0
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Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
Item non-
response
Item non-
response 
+ declared 
missing 
values
Item non-
response 
after 
imputation
(Sub)
question
Label
% % % % % % % % %
Q36m
Unwanted sex
16.3 22.5 31.0
Q36n
Unsafe sex
16.3 22.5 34.5
Q36o
Drunk drive
16.3
Q37
Substance use by siblings
Q37a
Sibling smokes
3.7 5.6 6.2 7.5 6.0 7.5
Q37b
Sibling drinks
8.8 10.5 13.0 14.0 12.9 16.0
Q37c
Sibling drunk
8.4 9.5 13.0 14.1 13.5 16.6
Q37d
Sibling 
cannabis
9.1 10.5 13.5 14.3 13.5 16.3
Q37e
Sibling tranq.
9.1 10.5 13.3 14.5 15.4 18.2
Q37g
Sibling medic.
8.8 10.2 13.3 14.4 14.1 16.6
Q37h
Sibling heroin
8.8 10.2 13.5 14.4 14.1 16.9
Q37f
Sibling ecstasy
8.8 10.0 13.5 14.4 14.1 16.6
Q37i
Sibling cocaine
9.1 10.2 13.4 14.4 14.1 16.9
Q38
Educ. father
2.6 6.7 9.9 21.0 6.9 11.6
Q39
Educ. mother
2.1 5.6 7.5 14.6 5.0 5.3
Q40
Status family
2.6 5.1 5.3
Q41
Household composition
Q41a
Type household
3.0 7.4 3.4
Q41b
Siblings?
3.0 7.4 3.4
Q42
Satisfaction relationships
Q42a
Relation father
1.4 6.2 3.1
Q42b
Relation mother
3.3 9.9 9.7
Q42d
Relation sibling
2.3 9.7 8.8
Q42c
Relation friends
2.6 10.5 8.5
Q43
Sat. Evening
27.4 17.2 23.2
Q44
Honest cann.
10.2 17.6 15.0
Q45
Honest heroin
10.9 18.8 16.3
Q46a
Money
18.4 22.9 17.6
Q46b
Money source
16.0 11.8 10.0
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ANNEX 3: PATTERNS OF ITEM NON-RESPONSE IN TABLE FORMAT QUESTIONS
Table 10: Non-response patterns in Q3 – doing things
Tabulated Patterns
c
116
X 387
Number of Cases
116
271
Q
3
a
Q
3
b
Q
3
c
Q
3
d
Q
3
e
Q
3
f
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 1  Algeria
c. 
Tabulated Patterns
c
604
X 806
Number of Cases
604
202
Q
3
a
Q
3
b
Q
3
c
Q
3
d
Q
3
e
Q
3
f
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
271
X X X X X 310
Number of Cases
271
10
Q
3
a
Q
3
b
Q
3
c
Q
3
d
Q
3
e
Q
3
f
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 3  Morocco
c. 
38
Table 11: Non-response patterns in Q4 – Missing school
Tabulated Patterns
c
98
X 244
X X 390
X X 124
Number of Cases
98
146
142
21
Q
4
a
Q
4
b
Q
4
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 1  Algeria
c. 
Tabulated Patterns
c
510
X 546
X X 847
X 551
X X 645
X X X 994
Number of Cases
510
36
260
41
93
38
Q
4
a
Q
4
b
Q
4
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
177
X 193
X X 278
X X 224
Number of Cases
177
16
83
29
Q
4
a
Q
4
b
Q
4
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 3  Morocco
c. 
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Table 12: Non-response patterns in Q8 – Prevalence of alcohol
Tabulated Patterns
c
355
X X 401
X X X 430
Number of Cases
355
45
26
Q
8
a
Q
8
b
Q
8
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 1  Algeria
c. 
Tabulated Patterns
c
668
X X 951
X X X 994
Number of Cases
668
275
42
Q
8
a
Q
8
b
Q
8
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
220
X X 306
Number of Cases
220
80
Q
8
a
Q
8
b
Q
8
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 3  Morocco
c. 
40
Table 13: Non-response patterns in Q10 – Last month prevalence of alcoholic drinks 
Tabulated Patterns
c
371
X X X 430
Number of Cases
371
41
Q
1
0
a
Q
1
0
b
Q
1
0
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 1  Algeria
c. 
Tabulated Patterns
c
836
X X 927
X X X 994
Number of Cases
836
74
64
Q
1
0
a
Q
1
0
b
Q
1
0
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
264
X X 302
X X X 319
Number of Cases
264
35
15
Q
1
0
a
Q
1
0
b
Q
1
0
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 3  Morocco
c. 
41
Table 14: Non-response patterns in Q17 - Perceived effects of alcohol drinking
Tabulated Patterns
c
256
X X X X X X X X X X X X 430
Number of Cases
256
56
Q
1
7
a
Q
1
7
b
Q
1
7
c
Q
1
7
d
Q
1
7
e
Q
1
7
f
Q
1
7
g
Q
1
7
h
Q
1
7
i
Q
1
7
j
Q
1
7
k
Q
1
7
l
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not
used.
b. 
COUNTRY = 1  Algeria
c. 
Tabulated Patterns
c
465
X X X X X X X X X X X 625
X X X X X X X X X X X X 994
X X X X X X X X X X X 589
Number of Cases
465
45
281
35
Q
1
7
a
Q
1
7
b
Q
1
7
c
Q
1
7
d
Q
1
7
e
Q
1
7
f
Q
1
7
g
Q
1
7
h
Q
1
7
i
Q
1
7
j
Q
1
7
k
Q
1
7
l
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not
used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
162
X X X X X X X X X X X 225
X X X X X X X X X X X X 319
X X X X X X X X X X X 199
Number of Cases
162
15
60
10
Q
1
7
a
Q
1
7
b
Q
1
7
c
Q
1
7
d
Q
1
7
e
Q
1
7
f
Q
1
7
g
Q
1
7
h
Q
1
7
i
Q
1
7
j
Q
1
7
k
Q
1
7
l
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not
used.
b. 
COUNTRY = 3  Morocco
c. 
42
Table 15: Non-response patterns in Q18 – Prevalence of being drunk
Tabulated Patterns
c
362
X X 395
X X X 430
Number of Cases
362
32
33
Q
1
8
a
Q
1
8
b
Q
1
8
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 1  Algeria
c. 
Tabulated Patterns
c
704
X X 944
X X X 994
Number of Cases
704
239
49
Q
1
8
a
Q
1
8
b
Q
1
8
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
213
X X 295
X X X 319
Number of Cases
213
80
18
Q
1
8
a
Q
1
8
b
Q
1
8
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 3  Morocco
c. 
43
Table 16: Non-response patterns in Q21 – Having heard of certain drugs
Tabulated Patterns
c
225
X 323
X X X X X X 253
X X X X X X X 381
X X X X X X X X X 278
Number of Cases
225
98
14
20
14
Q
2
1
a
Q
2
1
b
Q
2
1
c
Q
2
1
d
Q
2
1
e
Q
2
1
f
Q
2
1
g
Q
2
1
h
Q
2
1
i
Q
2
1
j
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with
X) are not used.
b. 
COUNTRY = 1  Algeria
c. 
Tabulated Patterns
c
704
X 743
X X X X X X X X X 829
X X X X X X X X X X 994
Number of Cases
704
39
37
58
Q
2
1
a
Q
2
1
b
Q
2
1
c
Q
2
1
d
Q
2
1
e
Q
2
1
f
Q
2
1
g
Q
2
1
h
Q
2
1
i
Q
2
1
j
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with
X) are not used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
135
X 181
X X X X X X 160
X X X X X X X X 252
X X X X X X X X X 278
X X X X X X X X X 205
X X X X X X X X X X 319
Number of Cases
135
46
12
10
10
25
10
Q
2
1
a
Q
2
1
b
Q
2
1
c
Q
2
1
d
Q
2
1
e
Q
2
1
f
Q
2
1
g
Q
2
1
h
Q
2
1
i
Q
2
1
j
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with
X) are not used.
b. 
COUNTRY = 3  Morocco
c. 
44
Table 17: Non-response patterns in Q23 – Prevalence of cannabis
Tabulated Patterns
c
373
X X X 430
X X 401
Number of Cases
373
25
28
Q
2
3
a
Q
2
3
b
Q
2
3
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 1  Algeria
c. 
Tabulated Patterns
c
748
X X 978
Number of Cases
748
227
Q
2
3
a
Q
2
3
b
Q
2
3
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
217
X X 307
Number of Cases
217
88
Q
2
3
a
Q
2
3
b
Q
2
3
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 3  Morocco
c. 
45
Table 18: Non-response patterns in Q24 – Prevalence of sniffing / inhaling
Tabulated Patterns
c
371
X X 404
X X X 430
Number of Cases
371
33
26
Q
2
4
a
Q
2
4
b
Q
2
4
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 1  Algeria
c. 
Tabulated Patterns
c
737
X X 976
Number of Cases
737
237
Q
2
4
a
Q
2
4
b
Q
2
4
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
218
X X 308
Number of Cases
218
87
Q
2
4
a
Q
2
4
b
Q
2
4
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 3  Morocco
c. 
46
Table 19: Non-response patterns in Q26 – Lifetime prevalence of certain drugs
Tabulated Patterns
c
0
X 382
X X X X X X X X X X X X 405
X X X X X X X X X X X X X 430
Number of Cases
0
382
21
18
Q
2
6
a
Q
2
6
b
Q
2
6
c
Q
2
6
d
Q
2
6
e
Q
2
6
f
Q
2
6
g
Q
2
6
i
Q
2
6
j
Q
2
6
k
Q
2
6
l
Q
2
6
m
Q
2
6
n
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 1  Algeria
c. 
Tabulated Patterns
c
0
X 877
X X X X X X X X X X X X 959
Number of Cases
0
877
63
Q
2
6
a
Q
2
6
b
Q
2
6
c
Q
2
6
d
Q
2
6
e
Q
2
6
f
Q
2
6
g
Q
2
6
i
Q
2
6
j
Q
2
6
k
Q
2
6
l
Q
2
6
m
Q
2
6
n
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
0
X X 272
X X X X X X X X X X X X 300
Number of Cases
0
272
25
Q
2
6
a
Q
2
6
b
Q
2
6
c
Q
2
6
d
Q
2
6
e
Q
2
6
f
Q
2
6
g
Q
2
6
i
Q
2
6
j
Q
2
6
k
Q
2
6
l
Q
2
6
m
Q
2
6
n
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 3  Morocco
c. 
47
Table 20: Non-response patterns in Q26_2 - Last month prevalence of certain drugs (Libya only)
Tabulated Patterns
c
870
X X X X X X X X X X X 945
X X X X X X X X X X X X 994
Number of Cases
870
65
34
Q
2
6
_
2
a
Q
2
6
_
2
b
Q
2
6
_
2
c
Q
2
6
_
2
d
Q
2
6
_
2
e
Q
2
6
_
2
f
Q
2
6
_
2
g
Q
2
6
_
2
i
Q
2
6
_
2
j
Q
2
6
_
2
k
Q
2
6
_
2
l
Q
2
6
_
2
n
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not
used.
b. 
COUNTRY = 2  Libya
c. 
Table 21: Non-response patterns in Q26_3 - Last year prevalence of certain drugs (Libya only)
Tabulated Patterns
c
870
X X X X X X X X X X X X 994
X X X X X X X X X X X 944
Number of Cases
870
39
61
Q
2
6
_
3
a
Q
2
6
_
3
b
Q
2
6
_
3
c
Q
2
6
_
3
d
Q
2
6
_
3
e
Q
2
6
_
3
f
Q
2
6
_
3
g
Q
2
6
_
3
i
Q
2
6
_
3
j
Q
2
6
_
3
k
Q
2
6
_
3
l
Q
2
6
_
3
n
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not
used.
b. 
COUNTRY = 2  Libya
c. 
Table 22: Non-response patterns in Q27 – Age of first use of substances
Tabulated Patterns
c
0
X 377
X X X X X X X X X X X X X X X X 408
X X X X X X X X X X X X X X X X X 430
Number of Cases
0
377
21
20
Q
2
7
a
Q
2
7
b
Q
2
7
c
Q
2
7
d
Q
2
7
e
Q
2
7
f
Q
2
7
g
Q
2
7
h
Q
2
7
i
Q
2
7
j
Q
2
7
k
Q
2
7
l
Q
2
7
m
Q
2
7
n
Q
2
7
o
Q
2
7
p
Q
2
7
q
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 1  Algeria
c. 
48
Tabulated Patterns
c
0
X X X X X X X X X X X X X X X X X 994
Number of Cases
0
994
Q
2
7
a
Q
2
7
b
Q
2
7
c
Q
2
7
d
Q
2
7
e
Q
2
7
f
Q
2
7
g
Q
2
7
h
Q
2
7
i
Q
2
7
j
Q
2
7
k
Q
2
7
l
Q
2
7
m
Q
2
7
n
Q
2
7
o
Q
2
7
p
Q
2
7
q
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
231
X 242
X X X X X X X X X X X X X X X X X 319
X X X X X X X X X X X X X X X X 297
Number of Cases
231
11
11
17
Q
2
7
a
Q
2
7
b
Q
2
7
c
Q
2
7
d
Q
2
7
e
Q
2
7
f
Q
2
7
g
Q
2
7
h
Q
2
7
i
Q
2
7
j
Q
2
7
k
Q
2
7
l
Q
2
7
m
Q
2
7
n
Q
2
7
o
Q
2
7
p
Q
2
7
q
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 3  Morocco
c. 
Table 23: Non-response patterns in Q32 – Disapproval of substance use
Tabulated Patterns
c
0
X 396
Number of Cases
0
396
Q
3
2
a
Q
3
2
b
Q
3
2
c
Q
3
2
d
Q
3
2
e
Q
3
2
f
Q
3
2
g
Q
3
2
h
Q
3
2
i
Q
3
2
j
Q
3
2
k
Q
3
2
l
Q
3
2
m
Q
3
2
n
Q
3
2
o
Q
3
2
p
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 1  Algeria
c. 
49
Tabulated Patterns
c
838
X X X X X X X X X X X X X X X 934
X X X X X X X X X X X X X X X X 994
Number of Cases
838
52
57
Q
3
2
a
Q
3
2
b
Q
3
2
c
Q
3
2
d
Q
3
2
e
Q
3
2
f
Q
3
2
g
Q
3
2
h
Q
3
2
i
Q
3
2
j
Q
3
2
k
Q
3
2
l
Q
3
2
m
Q
3
2
n
Q
3
2
o
Q
3
2
p
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
243
X X X X X X X X X X X X X 271
X X X X X X X X X X X X X X X 304
X X X X X X X X X X X X X X X X 319
Number of Cases
243
11
21
10
Q
3
2
a
Q
3
2
b
Q
3
2
c
Q
3
2
d
Q
3
2
e
Q
3
2
f
Q
3
2
g
Q
3
2
h
Q
3
2
i
Q
3
2
j
Q
3
2
k
Q
3
2
l
Q
3
2
m
Q
3
2
n
Q
3
2
o
Q
3
2
p
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 3  Morocco
c. 
Table 24: Non-response patterns in Q33 – Risk perception of substance use
Tabulated Patterns
c
371
Number of Cases
371
Q
3
3
a
Q
3
3
b
Q
3
3
c
Q
3
3
d
Q
3
3
e
Q
3
3
f
Q
3
3
g
Q
3
3
h
Q
3
3
i
Q
3
3
j
Q
3
3
k
Q
3
3
l
Q
3
3
m
Q
3
3
n
Q
3
3
o
Q
3
3
p
Q
3
3
q
Q
3
3
r
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 1  Algeria
c. 
50
Tabulated Patterns
c
794
X X X X X X X X X X X X X X X X X X 994
X X X X X X X X X X X X X X X X X 915
Number of Cases
794
71
50
Q
3
3
a
Q
3
3
b
Q
3
3
c
Q
3
3
d
Q
3
3
e
Q
3
3
f
Q
3
3
g
Q
3
3
h
Q
3
3
i
Q
3
3
j
Q
3
3
k
Q
3
3
l
Q
3
3
m
Q
3
3
n
Q
3
3
o
Q
3
3
p
Q
3
3
q
Q
3
3
r
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
246
X X X X X X X X X X X X X X X X X 304
X X X X X X X X X X X X X X X X X X 319
X X X X X X X X X X X X 271
Number of Cases
246
15
10
11
Q
3
3
a
Q
3
3
b
Q
3
3
c
Q
3
3
d
Q
3
3
e
Q
3
3
f
Q
3
3
g
Q
3
3
h
Q
3
3
i
Q
3
3
j
Q
3
3
k
Q
3
3
l
Q
3
3
m
Q
3
3
n
Q
3
3
o
Q
3
3
p
Q
3
3
q
Q
3
3
r
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 3  Morocco
c. 
Table 25: Non-response patterns in Q34 – Perceived availability of substances
Tabulated Patterns
c
356
X X X X X X X X X X X X X X X 430
Number of Cases
356
19
Q
3
4
a
Q
3
4
b
Q
3
4
c
Q
3
4
d
Q
3
4
e
Q
3
4
f
Q
3
4
g
Q
3
4
h
Q
3
4
i
Q
3
4
j
Q
3
4
k
Q
3
4
l
Q
3
4
m
Q
3
4
n
Q
3
4
o
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 1  Algeria
c. 
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Tabulated Patterns
c
0
X 802
X X X X X X X X X X X X X X 889
X X X X X X X X X X X X X X X 994
Number of Cases
0
802
54
103
Q
3
4
a
Q
3
4
b
Q
3
4
c
Q
3
4
d
Q
3
4
e
Q
3
4
f
Q
3
4
g
Q
3
4
h
Q
3
4
i
Q
3
4
j
Q
3
4
k
Q
3
4
l
Q
3
4
m
Q
3
4
n
Q
3
4
o
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
250
X X X X X X X X X X X X X X X 319
X X X X X X X X X X X X X X 291
Number of Cases
250
23
17
Q
3
4
a
Q
3
4
b
Q
3
4
c
Q
3
4
d
Q
3
4
e
Q
3
4
f
Q
3
4
g
Q
3
4
h
Q
3
4
i
Q
3
4
j
Q
3
4
k
Q
3
4
l
Q
3
4
m
Q
3
4
n
Q
3
4
o
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 3  Morocco
c. 
Table 26: Non-response patterns in Q35 – Substance use by friends
Tabulated Patterns
c
387
X X X X X X X X X X X X 418
Number of Cases
387
13
Q
3
5
a
Q
3
5
b
Q
3
5
c
Q
3
5
d
Q
3
5
e
Q
3
5
f
Q
3
5
g
Q
3
5
h
Q
3
5
i
Q
3
5
j
Q
3
5
k
Q
3
5
l
Q
3
5
m
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 1  Algeria
c. 
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Tabulated Patterns
c
0
X X 873
X X X X X X X X X X X X 945
X X X X X X X X X X X X X 994
Number of Cases
0
873
57
46
Q
3
5
a
Q
3
5
b
Q
3
5
c
Q
3
5
d
Q
3
5
e
Q
3
5
f
Q
3
5
g
Q
3
5
h
Q
3
5
i
Q
3
5
j
Q
3
5
k
Q
3
5
l
Q
3
5
m
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
0
X 238
X X 253
X X X X X X X X X X X X 309
Number of Cases
0
238
15
21
Q
3
5
a
Q
3
5
b
Q
3
5
c
Q
3
5
d
Q
3
5
e
Q
3
5
f
Q
3
5
g
Q
3
5
h
Q
3
5
i
Q
3
5
j
Q
3
5
k
Q
3
5
l
Q
3
5
m
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 3  Morocco
c. 
Table 27: Non-response patterns in Q36 – Problems due to alcohol or drug use (Algeria: only due to 
alcohol use)
Tabulated Patterns
c
356
X X X X X X X X X X X X X 382
X X X X X X X X X X X X X X 430
Number of Cases
356
21
47
Q
3
6
_
a
Q
3
6
_
b
Q
3
6
_
c
Q
3
6
_
d
Q
3
6
_
e
Q
3
6
_
f
Q
3
6
_
g
Q
3
6
_
h
Q
3
6
_
i
Q
3
6
_
j
Q
3
6
_
k
Q
3
6
_
l
Q
3
6
_
m
Q
3
6
_
n
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 1  Algeria
c. 
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Tabulated Patterns
c
758
X X X X X X X X X X X X X 837
X X X X X X X X X X X X X X 994
Number of Cases
758
57
153
Q
3
6
a
Q
3
6
b
Q
3
6
c
Q
3
6
d
Q
3
6
e
Q
3
6
f
Q
3
6
g
Q
3
6
h
Q
3
6
i
Q
3
6
j
Q
3
6
k
Q
3
6
l
Q
3
6
m
Q
3
6
n
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
202
X X X X X X X X X X X X X 246
X X X X X X X X X X X X X X 319
Number of Cases
202
21
68
Q
3
6
a
Q
3
6
b
Q
3
6
c
Q
3
6
d
Q
3
6
e
Q
3
6
f
Q
3
6
g
Q
3
6
h
Q
3
6
i
Q
3
6
j
Q
3
6
k
Q
3
6
l
Q
3
6
m
Q
3
6
n
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked with X) are not used.
b. 
COUNTRY = 3  Morocco
c. 
Table 28: Non-response patterns in Q37 – Substance use by siblings
Tabulated Patterns
c
387
X X X X X X X X 414
X X X X X X X X X 430
Number of Cases
387
21
15
Q
3
7
a
Q
3
7
b
Q
3
7
c
Q
3
7
d
Q
3
7
e
Q
3
7
g
Q
3
7
h
Q
3
7
f
Q
3
7
i
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked
with X) are not used.
b. 
COUNTRY = 1  Algeria
c. 
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Tabulated Patterns
c
853
X X X X X X X X 932
X X X X X X X X X 994
Number of Cases
853
67
58
Q
3
7
a
Q
3
7
b
Q
3
7
c
Q
3
7
d
Q
3
7
e
Q
3
7
g
Q
3
7
h
Q
3
7
f
Q
3
7
i
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked
with X) are not used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
265
X X X X X X X X 300
X X X X X X X X X 319
Number of Cases
265
20
18
Q
3
7
a
Q
3
7
b
Q
3
7
c
Q
3
7
d
Q
3
7
e
Q
3
7
g
Q
3
7
h
Q
3
7
f
Q
3
7
i
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that pattern (marked
with X) are not used.
b. 
COUNTRY = 3  Morocco
c. 
Table 29: Non-response patterns in Q42 – Satisfaction with relationships
Tabulated Patterns
c
406
Number of Cases
406
Q
4
2
a
Q
4
2
b
Q
4
2
d
Q
4
2
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (13 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 1  Algeria
c. 
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Tabulated Patterns
c
868
X X X X 994
X X X 932
Number of Cases
868
53
30
Q
4
2
a
Q
4
2
b
Q
4
2
d
Q
4
2
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (30 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 2  Libya
c. 
Tabulated Patterns
c
276
X X X 309
Number of Cases
276
13
Q
4
2
a
Q
4
2
b
Q
4
2
d
Q
4
2
c
Missing Patterns
a
C
o
m
p
l
e
t
e
 
i
f
 
.
.
.
b
Patterns with less than 3% cases (10 or fewer) are not displayed.
Variables are not sorted.
a. 
Number of complete cases if variables missing in that
pattern (marked with X) are not used.
b. 
COUNTRY = 3  Morocco
c. 
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ANNEX 4: PROPOSED ALTERNATIVE MODEL MedSPAD QUESTIONNAIRE
Instructions for completion are not included in the model below. 
An Arabic translation of the model MEDSPAD questionnaire can be obtained from the Secretariat of 
the Pompidou Group [mailto:Florence.MABILEAU-WHOMSLEY@coe.int]
.
MODEL MEDSPAD QUESTIONNAIRE
RESPONDENT & FAMILY
1 What is your sex
1 Male
2 Female
2 How old are you
3 What was your average grade at the end of the last term
4 With whom do you live together
1 Father 2 Mother 3 Siblings 4 Other
5 What is the highest level of schooling your mother completed
1 Less than primary
2 Primary
3 Secondary
4 Higher
5 Don't know
6 What is the highest level of schooling your father completed
1 Less than primary
2 Primary
3 Secondary
4 Higher
5 Don't know
BEHAVIOUR
7 On how many days in the last 30 days have you been truant
8 How many evenings in thelast 30 days have you been out away from home
58
TOBACCO
9 Do some of your friends or family members smoke cigarettes
1 No 2 Yes
10 Have you ever smoked cigarettes
1 No 2 Yes
11 At what age age did you smoke for the first time
12 Have you smoked cigarettes in the last 12 months
1 No 2 Yes
13 Have you smoked cigarettes in the last 30 days
1 No 2 Yes
14 How much have you smoked in the last 30 days
1 Less than 1 cigarette a week
2 Less than 1 cigarette a day
3 1-5 cigarettes a day
4 6-10 cigarettes a day
5 11-20 cigarettes a day
6 more than 20 cigarettes a day
ALCOHOL
15 Do some of your friends or family members drink alcohol
1 No 2 Yes
16 Have you ever drunk alcohol 
1 No 2 Yes
17 At what age age did you drink alcohol for the first time
18 Have you drunk alcohol in the last 12 months
1 No 2 Yes
19 Have you drunk alcohol in the last 30 days
1 No 2 Yes
20
On how many days did you drink alcohol in the 
last 30 days
59
CANNABIS
21 Do some of your friends or family members take cannabis
1 No 2 Yes
22 Have you ever taken cannabis 
1 No 2 Yes
23 At what age age did you take cannabis for the first time
24 Have you taken cannabis in the last 12 months
1 No 2 Yes
25 Have you taken cannabis in the last 30 days
1 No 2 Yes
26
SEDATIVES AND TRANQUILLISERS
27 Do some of your friends or family members take sedatives or tranquillisers
1 No 2 Yes
28 Have you ever taken sedatives or tranquillisers
1 No 2 Yes
29 At what age age did you take sedatives or tranquillisers for the first time
30 Have you taken sedatives or tranquillisers in the last 12 months
1 No 2 Yes
31 Have you taken sedatives or tranquillisers in the last 30 days
1 No 2 Yes
32
On how many days did you take cannabis in the 
last 30 days
On how many days did you take sedatives or 
tranquillisers in the last 30 days
60
OTHER DRUGS
33 Do some of your friends or family members take any other drugs
1 No 2 Yes
34 Which drugs you know that some of them take
35 Have you ever taken any other drug in your life
1 No 2 Yes
36 Which other drugs have you ever taken
RISK PERCEPTIONS
37
1 No risk
2 Moderate risk
3 Great risk
4 Don't know
38
1 No risk
2 Moderate risk
3 Great risk
4 Don't know
39
1 No risk
2 Moderate risk
3 Great risk
4 Don't know
40
1 No risk
2 Moderate risk
3 Great risk
4 Don't know
How much do you think people risk harming themselves (physically or otherwise) if they smoke cigarettes 
once in a while
How much do you think people risk harming themselves (physically or otherwise) if they smoke cigarettes 
regularly
How much do you think people risk harming themselves (physically or otherwise) if they drink alcohol once 
in a while
How much do you think people risk harming themselves (physically or otherwise) if they drink alcohol 
regularly
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41
1 No risk
2 Moderate risk
3 Great risk
4 Don't know
42
1 No risk
2 Moderate risk
3 Great risk
4 Don't know
43
1 No risk
2 Moderate risk
3 Great risk
4 Don't know
44
1 No risk
2 Moderate risk
3 Great risk
4 Don't know
OPINIONS
45 Do you disapprove if people smoke cigarettes once in a while
1 Yes 2 No 3 Don't know
46 Do you disapprove if people smoke cigarettes regularly
1 Yes 2 No 3 Don't know
47 Do you disapprove if people drink alcohol once in a while
1 Yes 2 No 3 Don't know
48 Do you disapprove if people drink alcohol regularly
1 Yes 2 No 3 Don't know
49 Do you disapprove if people take cannabis once in a while
1 Yes 2 No 3 Don't know
50 Do you disapprove if people take cannabis regularly
1 Yes 2 No 3 Don't know
51
1 Yes 2 No 3 Don't know
52 Do you disapprove if people take sedatives or tranquillisers without a doctor's prescription regularly
1 Yes 2 No 3 Don't know
Do you disapprove if people take sedatives or tranquillisers without a doctor's prescription once in a while
How much do you think people risk harming themselves (physically or otherwise) if they take cannabis once 
in a while
How much do you think people risk harming themselves (physically or otherwise) if they take cannabis 
regularly
How much do you think people risk harming themselves (physically or otherwise) if they take sedatives or 
tranquillisers once in a while without a doctor's prescription or medical supervision
How much do you think people risk harming themselves (physically or otherwise) if they take sedatives or 
tranquillisers regularly without a doctor's prescription or medical supervision
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APPENDIX 5 : LIST OF POMPIDOU GROUP DOCUMENTS AND PUBLICATIONS 
Publications
The following publications are published by Council of Europe Publishing, Strasbourg and can be 
ordered from the Publishing Division at: 
publishing@coe.int
http://book.coe.int
Calculating the social cost of illicit drugs: Methods and tools for estimating the social cost of the use of 
psychotropic substances, 2001, Pierre Kopp, ISBN 92-871-4734-5. (Available in Russian, December 
2003.)
Contribution to the sensible use of benzodiazepines, seminar, 2002, ISBN 92-871- 4751-5.
Connecting research, policy and practice: lessons learned and challenges ahead, Strategic 
Conference, 2004, ISBN 92-871-5535-6
Development and improvement of substitution programmes, seminar, 2002, ISBN 92-871-4807-4.
Drugs and drug dependence: linking research, policy and practice, lessons learned, challenges ahead, 
Richard Hartnoll. Strategic Conference, 2004, ISBN 92-871-5490-2 
Drug use in prison – Project of the group of experts in epidemiology of drug problems, final report, 
2001, Richard Muscat, ISBN 92-871-4521-0.
Drug-misusing offenders and the criminal justice system: the period from the first contact with the 
police to and including sentencing, seminar, 2000, ISBN 91-871-3790-0.
Drug-misusing offenders in prison and after release, seminar, 2000, ISBN 92-871-4242-4.
Ethics and drug addiction, proceedings of a seminar which took place in Strasbourg on 6-7 February 
2003.
Multi-city network eastern Europe, 1997, Joint Pompidou Group/UNDCP project, extension of the 
multi-city network to central and eastern Europe. First city reports from: Bratislava, Budapest, Gdansk, 
Ljubljana, Prague, Sofia, Szeged, Varna, Warsaw, ISBN 92-871-3509-6. 
Multi-city study: drug misuse trends in thirteen European cities, 1998, ISBN 92-871-2392-6.
Pregnancy and drug misuse: up-date 2000, seminar proceedings, 2001, ISBN 92-871-4503-2.
Pregnancy and drug misuse, symposium proceedings, 1999, ISBN 92-871-3784-6.
Prisons, drugs and society, seminar proceedings, 2003, ISBN 92-871-5090-7.
Risk reduction linked to substances other than by injection, seminar proceedings, 2003, ISBN 92-871-
5329-9.
Road traffic and psychoactive substances, proceedings of a seminar which took place in Strasbourg in 
June 2003.*
Road traffic and drugs, seminar, 2000, ISBN 92-871-4145-2.
3rd multi-city study: drug use trends in European cities in the 1990s, 2001, Ruud Bless, ISBN 92-871-
4459-1.
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Treated drug users in 23 European cities – Data 1997, Pompidou Group project on treatment demand
final report, 1999, Michael Stauffacher, ISBN 92-871-4007-3.
Vocational rehabilitation for drug users in Europe, seminar, 2000, ISBN 92-871-4406-0.
Women and drugs/Focus on prevention, symposium, ISBN 92-871-3508-8.
Other publications
The ESPAD Report 2003: Alcohol and other drug use among students in 35 European countries, 
2000, Joint publication Pompidou Group/CAN, ISBN 91-7278-103-3.
This publication can be ordered from The Swedish Council for Information on Alcohol and other Drugs 
(CAN). Fax : +46 8 10 46 41 or e-mail : barbro.andersson@can.se
Estimating the prevalence of problem drug use in Europe, scientific monograph series n° 1, Joint 
publication Pompidou Group/EMCDDA, 1999, ISBN 92-9168-006-0.
This publication can be ordered from EMCDDA. Fax: +351 21 813 17 11/ e-mail: info@emcdda.org.
Joint Pompidou Group – EMCDDA scientific report 2000 – Treatment demand indicator : standard 
protocol 2.0 and technical annex, 2000; this can be downloaded in two parts at: 
http://www.emcdda.org
Documents
The following documents have been prepared by the Pomidou Group and can be obtained by 
contacting the Secretariat in Strasbourg, France, 67075 at: 
e-mail: pompidou.group@coe.int
http://www.coe.int/pompidou
tel: + 33 388 41 29 87 / fax: + 33 388 41 27 85
Benzodiazepine use: a report of a survey of benzodiazepine consumption in the member countries of
the Pompidou Group, Gary Stillwell and Jane Fountain, P-PG/Benzo (2002) 1. 
Estimating the social cost of illicit drugs in Poland, P-PG/Cost (2003) 2.
Follow-up project on treatment demand: tracking long-term trends, final report by Michael Stauffacher 
et al, P-PG/Epid (2003) 37.
International drug court developments: models and effectiveness, Paul Moyle, September 2003, P-
PG/DrugCourts (2003) 3.
Missing pieces: developing drug information systems in central and eastern Europe, technical reports 
by Michael Stauffacher, co-ordinator (joint PG/UNDCP Project: extension of the Multi-city network to 
Central and Eastern European Europe), September 2001. 
Multi-city study of drug misuse in Amsterdam, Dublin, Hamburg, London, Paris, Rome, Stockholm, 
final report, Strasbourg, 1987.
Outreach work with young people, young drug users and young people at risk – Emphasis on 
secondary prevention, Petter Svensson, September 2003, P-PG/Prev (2003) 6.
The general potential of police prevention in the area of illicit drugs, Lorenz Böllinger, September 
2003, P-PG/Prev (2003) 2.
Targeted drug prevention – How to reach young people in the community? Report from the  Helsinki 
conference of November 2002.
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Political declaration, Pompidou Group Ministerial Conference, 17 October 2003, P-PG/Minconf (2003) 
3.
Pompidou Group multi-city study update report, 1999-2000, Ruud Bless, May 2002, P-PG/Epid 
(2002)11).
Pompidou Group work programme, 2004-2006, Pompidou Group Ministerial Conference, P-
PG/Minconf (2003) 4. 
Prisons, drugs and society: a consensus statement on principles, policies and practices, published by 
WHO (Regional Office for Europe) in partnership with the Pompidou Group, September 2002.
Problem drug use by women – Focus on community-based interventions, Dagmar Hedrich, P-
PG/Treatment (2000)3.
Seminar on Ethics, Professional Standards and Drug Addiction, February 2003, P-PG/Ethics (2003) 4

